| Literature DB >> 33319124 |
M Shaminur Rahman1, M Nazmul Hoque1,2, M Rafiul Islam1, Israt Islam1, Israt Dilruba Mishu1, Md Mizanur Rahaman1, Munawar Sultana1, M Anwar Hossain1.
Abstract
The ongoing mutations in the structural proteins of SARS-CoV-2 are the major impediment for prevention and control of the COVID-19 disease. Presently we focused on evolution of the envelope (E) protein, one of the most enigmatic and less studied protein among the four structural proteins (S, E, M and N) associated with multitude of immunopathological functions of SARS-CoV-2. In the present study, we comprehensively analyzed 81,818 high quality E protein sequences of SARS-CoV-2 globally available in the GISAID database as of 20 August 2020. Compared to Wuhan reference strain, our mutational analysis explored only 1.2 % (982/81818) mutant strains undergoing a total of 115 unique amino acid (aa) substitutions in the E protein, highlighting the fact that most (98.8 %) of the E protein of SARS-CoV-2 strains are highly conserved. Moreover, we found 58.77 % (134 of 228) nucleotides (nt) positions of SARS-CoV-2 E gene encountering a total of 176 unique nt-level mutations globally, which may affect the efficacy of real time RT-PCR-based molecular detection of COVID-19. Importantly, higher aa variations observed in the C-terminal domain (CTD) of the E protein, particularly at Ser55-Phe56, Arg69 and the C-terminal end (DLLV: 72-75) may alter the binding of SARS-CoV-2 Envelope protein to tight junction-associated PALS1 and thus could play a key role in COVID-19 pathogenesis. Furthermore, this study revealed the V25A mutation in the transmembrane domain which is a key factor for the homopentameric conformation of E protein. Our analysis also observed a triple cysteine motif harboring mutation (L39M, A41S, A41V, C43F, C43R, C43S, C44Y, N45R) which may hinder the binding of E protein with spike glycoprotein. These results therefore suggest the continuous monitoring of the structural proteins including the envelope protein of SARS-CoV-2 since the number of genome sequences from across the world are continuously increasing.Entities:
Keywords: CTD, C-terminal domain; E, envelope; Envelope protein; M, membrane; Mutations; N, nucleocapsid; NC, negatively charged; NP, non-polar; PC, positively charged; S, spike; SARS-CoV-2; SARS-CoV-2, Severe Acute Respiratory Syndrome Coronavirus-2; TMD, transmembrane domain; Transmembrane domain; Triple cysteine motif; aa, amino acid; nt, nucleotide
Year: 2020 PMID: 33319124 PMCID: PMC7723457 DOI: 10.1016/j.genrep.2020.100997
Source DB: PubMed Journal: Gene Rep ISSN: 2452-0144
Fig. 1Overview and variability coefficient of the envelope (E) protein of SARS-CoV-2. (A) Mapping and frequency distribution of mutations in the E protein of SARS-CoV-2 strains through Loliplot visualization. (B) Wu-Kabat variability coefficient of E protein of SARS-CoV-2. Here, variability coefficient 1 indicates the conservancy, whereas coefficients ˃ 1 indicate relative variability of the respective positions. The more the coefficient value the more the variability or diversity (Supplementary Data 1).
Overview and variability coefficient of the envelope (E) protein of SARS-CoV-2. (A) Mapping and frequency distribution of mutations in the E protein of SARS-CoV-2 strains through Loliplot visualization. (B) Wu-Kabat variability coefficient of E protein of SARS-CoV-2. Here, variability coefficient 1 indicates the conservancy, whereas coefficients ˃ 1 indicate relative variability of the respective positions. The more the coefficient value the more the variability or diversity (Supplementary Data 1).
Amino acid (aa) variation in envelope (E) protein of SARS-CoV-2.
| Position | Number of aa variations | aa (Ref:position:strain) | Reference aa characteristics | Strains aa characteristics |
|---|---|---|---|---|
| 72 | 6 | D72Y,D72G,D72H,D72N,D72V,D72A | A | P,NP,B,P,NP,NP |
| 5 | 4 | V5I,V5F,V5A,V5L | NP | NP,NP,NP,NP |
| 7 | 3 | E7K,E7Q,E7D | A | B,P,A |
| 8 | 3 | E8G,E8D,E8K | A | NP,A,B |
| 24 | 3 | V24M,V24L,V24A | NP | NP,NP,NP |
| 37 | 3 | L37H,L37F,L37R | NP | B,NP,B |
| 43 | 3 | C43F,C43R,C43S | NP | NP,B,P |
| 52 | 3 | V52I,V52L,V52E | NP | NP,NP,A |
| 58 | 3 | V58F,V58L,V58A | NP | NP,NP,NP |
| 61 | 3 | R61H,R61C,R61L | B | B, P,NP |
| 68 | 3 | S68F,S68C,S68Y | P | NP,NP,P |
| 70 | 3 | V70F,V70I,V70A | NP | NP,NP,NP |
| 71 | 3 | P71L,P71S,P71H | NP | NP,P,B |
| 10 | 2 | G10C,G10V | NP | NP,NP |
| 16 | 2 | S16N,S16G | P | P,NP |
| 17 | 2 | V17L,V17A | NP | NP,NP |
| 19 | 2 | L19S,L19F | NP | P,NP |
| 20 | 2 | F20I,F20L | NP | NP,NP |
| 21 | 2 | L21F,L21P | NP | NP,NP |
| 22 | 2 | A22V,A22S | NP | NP,P |
| 27 | 2 | L27F,L27S | NP | NP,P |
| 30 | 2 | T30I,T30A | P | NP,NP |
| 31 | 2 | L31P,L31I | NP | NP,NP |
| 41 | 2 | A41S,A41V | NP | P,NP |
| 46 | 2 | I46V,I46F | NP | NP,NP |
| 47 | 2 | V47F,V47G | NP | NP,NP |
| 50 | 2 | S50I,S50G | P | NP,NP |
| 51 | 2 | L51F,L51V | NP | NP,NP |
| 62 | 2 | V62F,V62D | NP | NP,A |
| 64 | 2 | N64K,N64S | P | B,P |
| 66 | 2 | N66T,N66H | P | P,B |
| 69 | 2 | R69I,R69K | B | NP,B |
| 73 | 2 | L73F,L73V | NP | NP,NP |
| 74 | 2 | L74P,L74V | NP | NP,NP |
| 75 | 2 | V75L,V75F | NP | NP,NP |
NP = non-polar, P = polar, B = basic, A = acidic.
Effects of mutation on E protein structure stability using Gibbs free energy (ΔΔG = ΔGmutant − ΔGWT) in FoldX.
| SI no. | Mutation | Number of observed strains | ΔΔG (kcal/mol) | Stability changes |
|---|---|---|---|---|
| 1 | S68F | 205 | −0.43159 | Slightly stabilizing |
| 2 | L73F | 100 | 0.091489 | Neutral |
| 3 | R69I | 88 | −0.0100619 | Neutral |
| 4 | P71L | 59 | −0.528276 | Slightly stabilizing |
| 5 | S55F | 40 | −0.170826 | Neutral |
| 6 | V62F | 39 | 3.03747 | Highly destabilizing |
| 7 | T9I | 38 | 1.34748 | Destabilizing |
| 8 | L21F | 32 | 0.332089 | Neutral |
| 9 | T30I | 29 | −0.727664 | Stabilizing |
| 10 | V24M | 26 | −1.80842 | Stabilizing |
| 11 | V75L | 22 | −1.50965 | Stabilizing |
| 12 | V58F | 20 | −0.162121 | Slightly stabilizing |
| 13 | D72H | 20 | 0.164999 | Neutral |